TanyaMaryaWildesMDMSCI

Oncology • Saint Louis, MO

Physician

Join to view full profile

Dr. Wildes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wildes' full profile

Already have an account?

Office
Not applicable
Saint Louis, MO 63129

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Geriatric Medicine (Internal Medicine), 2008 - 2009
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2005 - 2008
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2002 - 2005
Washington University in St. Louis School of MedicineClass of 2002

Certifications & Licensure

IA State Medical License 2023 - 2026
MO State Medical License 2009 - 2026
NE State Medical License 2022 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Start of enrollment: 2011 May 10
Active, not recruiting
Phase 1
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Start of enrollment: 2011 Jan 01
Terminated
Phase 3
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study Start of enrollment: 2011 Sep 09
Active, not recruiting
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer Start of enrollment: 2013 Feb 01
Completed
Phase 2
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07
Completed
Phase 1
Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer Start of enrollment: 2013 Jan 10
Terminated
Phase 3
Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) Start of enrollment: 2013 May 31
Completed
Phase 1
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
PD 0332991 and Cetuximab in Patients With Incurable SCCHN Start of enrollment: 2014 Jun 17
Completed
Phase 1, Phase 2
Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01
Completed
Aging, Geriatric Syndromes and Clonal Hematopoiesis Start of enrollment: 2016 Mar 10
Recruiting
Adaptation of the STEPPING ON Fall Prevention Program for Older Adults Receiving Cancer Therapy Start of enrollment: 2016 Jun 09
Completed
Not Applicable
Optimizing Fall-risk Prediction in Older Adults With Cancer Start of enrollment: 2016 Oct 12
Completed
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy Start of enrollment: 2017 Jul 14
Active, not recruiting
Phase 3
Lenalidomide Adherence in Older Adults Start of enrollment: 2019 Dec 13
Terminated
Join now to see all

Publications & Presentations

PubMed

Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice.
Matthew J Pianko, Hira S Mian, Kelly L Schoenbeck, Tanya M Wildes
Leukemia & Lymphoma. 2025-02-01
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed mul...
Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves
Future Oncology. 2025-01-01
2 citations
Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospe...
Mina S Sedrak, Can-Lan Sun, Marie Bae, Rachel A Freedman, Allison Magnuson
Journal of Cancer Survivorship. 2024-08-01

Journal Articles

Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer
Eric P Winer, Louise C Walter, Mina S Sedrak, Tanya M Wildes, Stuart M Lichtman, Kathryn J Ruddy, JAMA Oncology

Abstracts/Posters

The Ire of IRE1_: Overexpression of IRE1_ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1_ Expression Is Predictive of Therapy ...
Tanya M Wildes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma
Tanya M Wildes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults with Multiple Myeloma to Drive Personalized Treatment Decisions
Tanya M Wildes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment
Tanya M. Wildes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Tanya M Wildes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Frailty in Older Adults with Multiple Myeloma: A Study of United States Veterans
Tanya M Wildes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Managing High Risk-Myeloma in Older Patients
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Friday Scientific Workshop on Hematology and Aging: From Bleeding Disorders to Malignant Hematology
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Approach to the Treatment of the Older, Unfit Patient With Myeloma: From Diagnosis to Relapse
60th American Society of Hematology Annual Meeting - 12/1/2018
Career-Development Lunch Sessions: Adult Clinical Malignant Hematology/BMT
60th American Society of Hematology Annual Meeting - 12/1/2018
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hematology & Aging: Scientific Advances From Sickle Cell Disease to Malignant Hematology
60th American Society of Hematology Annual Meeting - 11/30/2018
Utilizing Geriatric Assessment to Decrease Treatment-Associated Toxicity in Clinical Practice
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

Medical Research Highlights, February 2025February 15th, 2025
Modified Quadruplet Regimen Effective in Older Myeloma PatientsFebruary 4th, 2025
Ellen DeGeneres Has Lost 1 Million Viewers Following Workplace Misconduct AllegationsMarch 22nd, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

TanyaMaryaWildesMDMSCI

Dr. Wildes is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.